*Terms and conditions apply. Scroll down or click here.
Only you (the patients' healthcare professional) can determine if brand-name DILANTIN is the
  right treatment choice for your patients. When changing the dosage form or brand, you
  should carefully monitor patients' phenytoin serum levels.

Indication
DILANTIN is indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures, and for the prevention and treatment of seizures occurring during or following neurosurgery.
Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Important Safety Information

Phenytoin is contraindicated in patients with a history of hypersensitivity to phenytoin, any of the inactive ingredients, or other hydantoins.

Coadministration of DILANTIN is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus.

When a change in the dosage form or brand is prescribed, careful monitoring of phenytoin serum levels should be carried out.

Antiepileptic drugs, including DILANTIN, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any antiepileptic drug should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Patients should be instructed to call their physician if a skin rash or any of the symptoms listed below appear.

DILANTIN should be discontinued if a skin rash appears. If the rash is exfoliative, purpuric, or bullous or if lupus erythematosus, Stevens-Johnson syndrome, or toxic epidermal necrolysis is suspected, use of this drug should not be resumed and alternative therapy should be considered. If a rash occurs, the patient should also be evaluated for signs and symptoms of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Some of these events have been fatal or life-threatening.

Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with DILANTIN. In these patients with acute hepatotoxicity, DILANTIN should be immediately discontinued and not re-administered.

Hematopoietic complications, some fatal, have occasionally been reported in association with administration of DILANTIN. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have been reports suggesting a relationship between phenytoin and the development of lymphadenopathy, including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease.

The chronic use of DILANTIN in patients with epilepsy has been associated with decreased bone mineral density and bone fractures and is considered to be due to phenytoin's interference with vitamin D metabolism.

The importance of good dental hygiene should be stressed in order to minimize the development of gingival hyperplasia and its complications.

Patients taking DILANTIN should be advised of the importance of informing the physician of any clinical condition. Patients with impaired liver function, elderly patients, or those who are gravely ill may show early signs of toxicity.

Caution should be exercised in using this medication in patients suffering from porphyria.

Hyperglycemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.

An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential harm to the fetus. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. Infant breast-feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.

There are many drugs that may increase or decrease phenytoin levels or may be affected by phenytoin.

Acute alcoholic intake may increase phenytoin serum levels, while chronic alcohol use may decrease serum levels.

The most common side effects encountered with phenytoin therapy are referable to the central nervous system and include nystagmus, ataxia, slurred speech, decreased coordination, somnolence and mental confusion.

Please see full Prescribing Information and Medication Guide.

Terms and Conditions
By using the DILANTIN $4 Co-Pay Card, you acknowledge that you currently meet the eligibility criteria and will comply with the following terms and conditions.

  • The Card is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, or other federal or state healthcare programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico [formerly known as "La Reforma De Salud"])
  • The Card is not valid for prescriptions that are eligible to be reimbursed by private insurance plans or other health or pharmacy benefit programs that reimburse you for the entire cost of your prescription drugs
  • You must be 18 or older
  • By using the Card, you will pay a minimum of $4 per fill and receive savings of up to $50 per fill, for a maximum savings of $600 per card
  • You must deduct the value received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
  • The Card is not valid for Massachusetts residents whose prescriptions are covered in whole or in part by third-party insurance, or where otherwise prohibited by law
  • The Card cannot be combined with any other rebate or coupon, free trial, or similar offer for the specified prescription
  • The Card will be accepted only at participating pharmacies
  • The Card is not health insurance
  • This offer is good only in the United States and Puerto Rico
  • The Card is limited to one per person during this offering period and is not transferable
  • Pfizer reserves the right to rescind, revoke, or amend the Card without notice
  • Offer expires 12/31/14

No membership fees apply. For help with the DILANTIN $4 Co-Pay Card, call 1-866-590-9400 or visit DILANTIN.com. Pfizer Inc, DILANTIN, 235 East 42nd Street, New York, NY 10017.

Please scroll for Important Safety Information and Indication

Important Safety Information

Phenytoin is contraindicated in patients with a history of hypersensitivity to phenytoin, any of the inactive ingredients, or other hydantoins.

Coadministration of DILANTIN® (Extended Phenytoin Sodium Capsules, USP) is contraindicated with delavirdine due to potential for loss of virologic response and possible resistance to delavirdine or to the class of non-nucleoside reverse transcriptase inhibitors.

Abrupt withdrawal of phenytoin in epileptic patients may precipitate status epilepticus.

When a change in the dosage form or brand is prescribed, careful monitoring of phenytoin serum levels should be carried out.

Antiepileptic drugs, including DILANTIN, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any antiepileptic drug should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.

Patients should be instructed to call their physician if a skin rash or any of the symptoms listed below appear.

DILANTIN should be discontinued if a skin rash appears. If the rash is exfoliative, purpuric, or bullous or if lupus erythematosus, Stevens-Johnson syndrome, or toxic epidermal necrolysis is suspected, use of this drug should not be resumed and alternative therapy should be considered. If a rash occurs, the patient should also be evaluated for signs and symptoms of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS). Some of these events have been fatal or life-threatening.

Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with DILANTIN. In these patients with acute hepatotoxicity, DILANTIN should be immediately discontinued and not re-administered.

Hematopoietic complications, some fatal, have occasionally been reported in association with administration of DILANTIN. These have included thrombocytopenia, leukopenia, granulocytopenia, agranulocytosis, and pancytopenia with or without bone marrow suppression. There have been reports suggesting a relationship between phenytoin and the development of lymphadenopathy, including benign lymph node hyperplasia, pseudolymphoma, lymphoma, and Hodgkin's disease.

The chronic use of DILANTIN in patients with epilepsy has been associated with decreased bone mineral density and bone fractures and is considered to be due to phenytoin's interference with vitamin D metabolism.

The importance of good dental hygiene should be stressed in order to minimize the development of gingival hyperplasia and its complications.

Patients taking DILANTIN should be advised of the importance of informing the physician of any clinical condition. Patients with impaired liver function, elderly patients, or those who are gravely ill may show early signs of toxicity.

Caution should be exercised in using this medication in patients suffering from porphyria.

Hyperglycemia, resulting from the drug's inhibitory effects on insulin release, has been reported. Phenytoin may also raise the serum glucose level in diabetic patients.

An increase in seizure frequency may occur during pregnancy because of altered phenytoin pharmacokinetics. If this drug is used during pregnancy, or if the patient becomes pregnant while taking the drug, the patient should be apprised of the potential harm to the fetus. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero. Infant breast-feeding is not recommended for women taking this drug because phenytoin appears to be secreted in low concentrations in human milk.

There are many drugs that may increase or decrease phenytoin levels or may be affected by phenytoin.

Acute alcoholic intake may increase phenytoin serum levels, while chronic alcohol use may decrease serum levels.

The most common side effects encountered with phenytoin therapy are referable to the central nervous system and include nystagmus, ataxia, slurred speech, decreased coordination, somnolence and mental confusion.

Indication

DILANTIN is indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures, and for the prevention and treatment of seizures occurring during or following neurosurgery.
Phenytoin serum level determinations may be necessary for optimal dosage adjustments.

Please see full Prescribing Information and Medication Guide.